Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) PT at $15.17

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned an average rating of “Hold” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $15.17.

Several equities analysts have commented on the stock. UBS Group dropped their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus lowered their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st.

Elanco Animal Health Price Performance

ELAN opened at $10.40 on Wednesday. The firm has a market cap of $5.14 billion, a price-to-earnings ratio of 25.99, a PEG ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock’s 50-day moving average price is $11.23 and its 200 day moving average price is $12.45. Elanco Animal Health has a 12-month low of $10.03 and a 12-month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 EPS. As a group, sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares of the company’s stock, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.57% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Several institutional investors have recently modified their holdings of ELAN. Wilmington Savings Fund Society FSB purchased a new position in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health during the fourth quarter worth about $29,000. Jones Financial Companies Lllp increased its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. Finally, MRP Capital Investments LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $61,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.